Immune Design
May 12, 2015

Immune Design to Report First Quarter 2015 Financial Results and Provide ASCO Clinical Research Update

SEATTLE and SOUTH SAN FRANCISCO, Calif., May 12, 2015 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced that it will report first quarter 2015 financial results prior to the opening of U.S. financial markets on Thursday, May 14, 2015. Immune Design management will host a webcast and conference call at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time on May 14, 2015 to discuss the first quarter 2015 financial results and provide an ASCO clinical research update.

The live call may be accessed by dialing 844-831-3023 for domestic callers and 920-663-6275 for international callers. A live webcast of the call will be available online from the investor relations section of the company website at and will be archived there for 90 days. A telephone replay of the call will be available for five days by dialing 855-859-2056 for domestic callers or 404-537-3406 for international callers and entering the conference code: 46914908.

About Immune Design

Immune Design is a clinical-stage immunotherapy company employing next-generation in vivo approaches to enable the body's immune system to fight disease. The company's technologies are engineered to activate the immune system's natural ability to generate and/or expand antigen-specific cytotoxic T cells, while enhancing other immune effectors, to fight cancer and other chronic diseases. CMB305 and G100, the two-pronged focus of Immune Design's ongoing immuno-oncology clinical programs, are the product of its two synergistic discovery platforms: ZVexTM and GLAASTM. Immune Design has offices in Seattle and South San Francisco. For more information, visit

CONTACT: Media Contact

         Julie Rathbun

         Rathbun Communications


         Investor Contact

         Shari Annes

         Annes Associates


company logo

Source: Immune Design

News Provided by Acquire Media